Tapentadol extended release in the management of peripheral diabetic neuropathic pain
نویسندگان
چکیده
Tapentadol, a μ-opioid agonist and norepinephrine reuptake inhibitor, has been found to be an effective medication for a wide variety of chronic pain conditions, including back pain, cancer-related pain, and arthritic pain. It has also been found to have fewer gastrointestinal side effects than more traditional opioid-based therapies. More recently, tapentadol extended release has been demonstrated to be effective in the management of painful diabetic neuropathy, an often debilitating condition affecting approximately one-third of all patients with diabetes. This review highlights the most up-to-date basic and clinical studies by focusing on the mechanisms of action of tapentadol and its clinical efficacy, especially with regard to painful diabetic neuropathy.
منابع مشابه
Tapentadol extended-release for treatment of chronic pain: a review
Tapentadol is a centrally acting analgesic with a dual mechanism of action of mu receptor agonism and norepinephrine reuptake inhibition. Tapentadol immediate-release is approved by the US Food and Drug Administration for the management of moderate-to-severe acute pain. It was developed to decrease the intolerability issue associated with opioids. Tapentadol extended-release has a 12-hour durat...
متن کاملA Pooled Analysis Evaluating the Efficacy and Tolerability of Tapentadol Extended Release for Chronic, Painful Diabetic Peripheral Neuropathy
BACKGROUND AND OBJECTIVE Data from two similarly designed studies of tapentadol extended release (ER) for managing neuropathic pain associated with diabetic peripheral neuropathy (DPN; NCT00455520, NCT01041859) in adults were pooled for this analysis, allowing a detailed evaluation of efficacy in patient subgroups and secondary endpoints. METHODS In each study, patients were titrated to their...
متن کاملA randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy.
OBJECTIVE This study evaluated the efficacy and tolerability of tapentadol extended release (ER) for the management of chronic pain associated with diabetic peripheral neuropathy (DPN). RESEARCH DESIGN AND METHODS Adults with moderate to severe DPN pain were titrated to tapentadol ER 100-250 mg bid during a 3-week open-label period; patients with ≥1-point reduction in pain intensity (11-point...
متن کاملTapentadol (Nucynta®) for the Treatment of Pain
DIABETES AND DEPRESSION: PATIENT CARE IMPACT AND MANAGEMENT OPTIONS n 2011, an estimated 1.5 billion or more people worldwide suffered from some type of chronic pain, with approximately 3% to 4.5% of the global population suffering from neuropathic pain.1 In fact, the U.S. represents the largest regional market for pain management worldwide, followed by Europe. The Asia -Pacific regional market...
متن کاملTapentadol extended release for the management of chronic neck pain
BACKGROUND The role of opioids in the management of chronic neck pain is still poorly investigated. No data are available on tapentadol extended release (ER). In this article, we present 54 patients with moderate-to-severe chronic neck pain treated with tapentadol ER. PATIENTS AND METHODS Patients received tapentadol ER 100 mg/day; dosage was then adjusted according to clinical needs. The fol...
متن کامل